Evidence map›Paper›PMID 41414827›Full record

ArticlePharmaceutical biology2026

Kaempferol activity on

Majed H Wakid, Eman S El-Wakil, Muslimah N Alsulami, Haytham Azab

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Majed H WakidDepartment of Medical Laboratory Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Eman S El-WakilDepartment of Parasitology, Theodor Bilharz Research Institute, Giza, Egypt.
Muslimah N AlsulamiDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Haytham AzabDepartment of Medical Parasitology, Misr University for Science and Technology, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextNo vaccine or effective therapy for cryptosporidiosis currently exists, except for nitazoxanide (NTZ), which has limited effectiveness in immunocompromised hosts. Kaempferol (KPF), a naturally occurring flavonoid, has various pharmacological effects and promising antiparasitic properties.

objectiveThe current work aimed to examine the impact of KPF compared with NTZ on MATERIALS AND

methodsThe present study utilized KPF and NTZ as multi-target ligands to predict, determine, and evaluate their

resultsThe DISCUSSION AND

conclusionKPF demonstrated the potential to mitigate the consequences of cryptosporidiosis and serve as an adjuvant agent to NTZ by reducing the oocyst burden, alleviating intestinal inflammation, and facilitating mucosal repair.

Indexed as

Antiparasitic AgentsCryptosporidiosisKaempferolsAnimalsCryptosporidium parvumDrug Evaluation, PreclinicalImmunocompromised HostIntestinesMaleMiceMolecular Docking SimulationNitro CompoundsNLR Family, Pyrin Domain-Containing 3 ProteinParasite Egg CountRandom AllocationReceptors, Cell SurfaceAntiparasitic AgentskaempferolKaempferolsnitazoxanideNitro CompoundsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseReceptors, Cell SurfaceThiazolesCryptosporidium parvumin silico molecular dockingkaempferolmicenitazoxanide

Identifiers

PMID41414827
PMCPMC12720632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.